Evidence map›Paper›PMID 41975702›Full record

ArticleDiagnostics (Basel, Switzerland)2026

Pathology-Driven Genomic Panels for Personalized Prognostic Stratification and Exploratory Therapeutic Prediction in Clear-Cell Renal Cell Carcinoma with Tumor Thrombus.

Chenghao Tan, Shiming He, Sainan Zhu, Qun He, Zhisong He, Liqun Zhou, Gengyan Xiong

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chenghao TanDepartment of Urology, Peking University First Hospital, Beijing 100034, China.ORCID 0009-0005-4209-8936
Shiming HeDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Sainan ZhuDepartment of Biostatistics, Peking University First Hospital, Beijing 100034, China.
Qun HeDepartment of Urological Pathology, Peking University First Hospital, Beijing 100034, China.
Zhisong HeDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Liqun ZhouDepartment of Urology, Peking University First Hospital, Beijing 100034, China.
Gengyan XiongDepartment of Urology, Peking University First Hospital, Beijing 100034, China.

Funding

Capital's Funds for Health Improvement and Research 2024-2-4078the Scientific and Technological Achievements Transformation Incubation Guidance Funding Project of Peking University First Hospital 2022CX10the Wuxi "Taihu Talents Program" Medical and Health High-level Talents Project
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clear-cell renal cell carcinomacompanion diagnosticsimmunotherapy responsemolecular pathologymultigene panelpersonalized oncologyprognostic biomarker

Identifiers

PMID41975702
PMCPMC13073698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.